Tempest Therapeutics, Inc. financial data

Symbol
TPST on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 400, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Millendo Therapeutics, Inc. (to 7/1/2021), OvaScience, Inc. (to 12/6/2018)
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 225 % -22.7%
Debt-to-equity 138 % -44%
Return On Equity -246 % +13.5%
Return On Assets -103 % -25.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.5M shares +105%
Common Stock, Shares, Outstanding 44M shares +99.5%
Entity Public Float 53.6M USD +235%
Common Stock, Value, Issued 44K USD +100%
Weighted Average Number of Shares Outstanding, Basic 27.9M shares +81%
Weighted Average Number of Shares Outstanding, Diluted 27.9M shares +81%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 13.6M USD +16.2%
Operating Income (Loss) -42M USD -44.1%
Nonoperating Income (Expense) 183K USD +308%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -41.8M USD -41.9%
Earnings Per Share, Basic -1.5 USD/shares +21.5%
Earnings Per Share, Diluted -1.5 USD/shares +21.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.3M USD -22.8%
Other Assets, Current 535K USD +457%
Assets, Current 31.5M USD -22%
Property, Plant and Equipment, Net 886K USD +5.48%
Operating Lease, Right-of-Use Asset 8.64M USD -13.2%
Other Assets, Noncurrent 485K USD +8.26%
Assets 41.5M USD -19.6%
Accounts Payable, Current 2.45M USD +190%
Employee-related Liabilities, Current 1.76M USD +14.2%
Accrued Liabilities, Current 2.73M USD +62.9%
Liabilities, Current 14.2M USD +51.1%
Operating Lease, Liability, Noncurrent 8.14M USD -11.1%
Liabilities 22.4M USD -9.96%
Retained Earnings (Accumulated Deficit) -207M USD -25.3%
Stockholders' Equity Attributable to Parent 19.1M USD -28.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 19.1M USD -28.5%
Liabilities and Equity 41.5M USD -19.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.19M USD +13.5%
Net Cash Provided by (Used in) Financing Activities 450K USD +923%
Net Cash Provided by (Used in) Investing Activities -168K USD -265%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 44M shares +99.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.31M USD -45.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 30.7M USD -22.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 326K USD +11.6%
Deferred Tax Assets, Valuation Allowance 177M USD +7.38%
Deferred Tax Assets, Gross 179M USD +6.99%
Depreciation 389K USD +2.1%
Payments to Acquire Property, Plant, and Equipment 168K USD +265%
Property, Plant and Equipment, Gross 2.21M USD +18.3%
Operating Lease, Liability, Current 869K USD -8.72%
Deferred Tax Assets, Operating Loss Carryforwards 144M USD +5.11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 5.24M USD +6.42%
Additional Paid in Capital 226M USD +17.8%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.54M USD -14.6%
Share-based Payment Arrangement, Expense 5.3M USD +108%
Interest Expense 1.49M USD -1.97%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%